Eisai announced it will launch two types of triple formulation combination packs containing Pariet for the treatment of Helicobacter pylori eradication in Japan. Pariet (rabeprazole sodium) is a proton pump inhibitor to prevent stomach acid from being excessively secreted. The drug is also used to treat gastric ulcers, reflux esophagitis, and duodenal ulcers due to its speed and efficacy in inhibiting acid secretion.
Three products will be featured in the launch. These include Rabecure Pack 400 and Rabecure Pack 800 for use in treatment of primary H. pylorieradication, and Rabefine pack for use in treatment of secondary H. pylori eradication. Rabecure Packs 400 and 800 package together in individual blister sheets containing a triple daily formulation dose of Pariet, clarithromycin, and amoxicillin hydrate. Rabefine packs a daily triple formulation dose of Pariet, metronidazole, and amoxicillin hydrate.
Successful eradication of H. pylori using Pariet and two antimicrobial agents depends on the patient’s adherence to the prescribed treatment regimen and schedule, the company said. “Taking the incorrect dose or missing doses altogether can lead not only to reduced eradication rates but also to bacterial resistance. With daily-dose blister sheets adopted for both the primary and secondary eradication combinations of Eisai's new triple formulation packs, the launch is expected to help ensure that H. pylori eradication therapy is administered more appropriately and with greater certainty, while also improving patient drug compliance and offering increased convenience in a medical setting.”
Eisai said it hopes to promote appropriate use of therapeutic agents in the treatment of H. pylori and associated diseases, as well as gastric cancer eradication.
The company won approval from the Ministry of Health, Labour and Welfare to manufacture and market the two combination types in Japan in August 2013. Japan’s National Health Insurance drug price list included all three Eisai products in December 2013.